amivantamab   Click here for help

GtoPdb Ligand ID: 10505

Synonyms: amivantamab-vmjw | JNJ-61186372 | JNJ-6372 | JNJ61186372 | Rybrevant®
Approved drug
amivantamab is an approved drug (FDA & EMA (2021))
Compound class: Antibody
Comment: Amivantamab (JNJ-61186372) is a bispecific monoclonal that targets EGFR and MET [2,4,7]. Examination of binding by surface plasmon resonance confirms that JNJ-61186372 can bind to EGFR and MET simultaneously [2]. JNJ-61186372 binding inhibits phosphorylation of both of the target receptor tyrosine kinases in vitro. Tackling the tyrosine kinases from outside the cell is hypothesised to override the issue of treatment resistance due to kinase mutations that frequently arise during therapy with intracellulary-acting small molecule kinase inhibitors [3,5-6].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Janssen R&D progressed this dual MET/EGFR monoclonal to clinical development for advanced NSCLC (see NCT02609776), and by 2020 it had reached Phase 3. At that time there was an expanded access program in place, to provide amivantamab treatment for patients with otherwise untreatable (progressing, platinum-based chemotherapy resistant), advanced NSCLC with EGFR exon 20 insertion mutations (see NCT04599712). The FDA granted accelerated approval for that indication in May 2021 [1]. FDA approval was expanded in September 2024, to include treatment of locally advanced/metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations where disease has progressed on/after EGFR tyrosine kinase inhibitor treatment.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02609776 Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Phase 1 Interventional Janssen Research & Development, LLC
NCT04487080 A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase 3 Interventional Janssen Research & Development, LLC
NCT04538664 A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Phase 3 Interventional Janssen Research & Development, LLC